Table 3 Research on SDC1 targeting in breast cancer
From: SDC1 is a critical transmembrane proteoglycan in breast cancer
Ligands | Targeted area | Antitumor affect | Research style | Style object | Reference |
|---|---|---|---|---|---|
BB4 (I131) | extracellular domain of mSDC1 | Inducing the death of tumor cells | Clinical model | Multiple myeloma patients | 87 |
BB-94 (MMP inhibitor) | Inhibiting shedding of mSDC1 | Inhibiting of chemotherapy-induced SDC1 shedding to form a microenvironment that promotes tumor recurrence | Pre-clinical model | Mouse | 89 |
All-trans retinoic acid (ATRA) | Reducing expression of sSDC1 | Providing chemical protective effect on lung cancer model induced by benzopyrene | Pre-clinical model | Mouse | 90 |
Zoledronic acid | Reducing expression of sSDC1 | Inhibiting bone metastasis | Pre-clinical model | Cell | 83 |
SSTN | Destructing of SDC1 and integrin complex | Inhibiting angiogenesis | Pre-clinical model | Mouse | 73 |